梅尔弗卢芬和合物在多发性骨髓瘤中的新兴作用
Nour Moukalled1, Iman Abou Dalle1, Jean El Cheikh1
1Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Current opinion in oncology
|September 9, 2024
概括
新的类药物合物,如梅尔芬,在复发性多发性髓瘤中显示出有前途. 在临床试验中,组合治疗,特别是与达拉图穆马布 (daratumumab) 组合治疗,改善了无进展生存率和应答率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤治疗已经取得了进展,改善了生存率,但面临着复发性疾病和异质性的挑战.
- 化剂具有历史意义,但受到毒性限制.
- 类药物合物代表了多发性骨髓瘤的新型治疗类.
研究的目的:
- 审查化剂在多发性骨髓瘤中的历史作用.
- 提供关于类药物联合体的最新数据,特别是用于治疗多发性骨髓瘤的梅尔芬.
- 探索复发性和耐火性多发性髓瘤的治疗策略.
主要方法:
- 对化剂的历史数据的审查.
- 对melflufen和基于melflufen的组合进行临床试验数据的分析.
- 评估无进展生存率和整体反应率.
主要成果:
- 与单剂达拉图穆马布相比,达拉图穆马布 - 梅尔夫 - 德克萨米的组合显著改善了无进展生存率 (P=0.0032) 和整体应答率 (P=0.03).
- 单剂梅尔芬在重度预治疗的患者中初步表现有前途.
- 随后对梅尔芬组合的分析表明了潜在的疗效.
结论:
- 像梅尔芬这样的类药物对复发性多发性骨髓瘤有兴趣.
- 最佳的患者选择和伴随剂的识别对于成功使用梅尔弗鲁芬至关重要.
- 对基于梅尔芬的组合药物的进一步研究可能会提供新的治疗途径.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
11.9K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
